Amlodipine 5 mg once daily is the drug of choice for managing hypertension in patients receiving capecitabine.
For antihypertensive-naive patients on capecitabine who develop hypertension, start with amlodipine 5 mg once daily and reassess blood pressure after 2 weeks. This recommendation comes from specialized guidance on managing bevacizumab-induced hypertension in cancer patients, which provides the most directly applicable evidence for chemotherapy-associated hypertension 1.
Initial Assessment and Treatment Thresholds
Before initiating antihypertensive therapy in capecitabine patients:
- Confirm elevated BP with home or ambulatory monitoring if clinic BP ≥150/95 mmHg
- Target BP <150/95 mmHg during active chemotherapy (more lenient than general population targets)
- Delay capecitabine if BP ≥160/100 mmHg until controlled
Stepwise Treatment Algorithm for Antihypertensive-Naive Patients
Step 1: Calcium Channel Blocker
- Amlodipine 5 mg once daily (preferred dihydropyridine CCB)
- Reassess BP after 2 weeks
- If inadequate control, increase to amlodipine 10 mg once daily
Step 2: Add ACE Inhibitor or ARB
- Perindopril 2 mg once daily OR
- Losartan 50 mg once daily
- Continue amlodipine at current dose
Step 3: Add Thiazide-Like Diuretic
- Indapamide 2.5 mg once daily
- Continue both previous medications
Step 4: Resistant Hypertension
- Consider increasing dose of ≥1 existing drug
- If serum potassium <4.5 mmol/L and normal renal function: add spironolactone 25 mg once daily 2
- Refer to hypertension specialist if BP remains ≥160/100 mmHg on ≥3 drugs
Rationale for Amlodipine as First-Line
The calcium channel blocker approach is preferred over ACE inhibitors/ARBs as initial therapy in cancer patients for several reasons:
- Immediate efficacy without titration delays common with RAS blockers
- No drug-drug interactions with capecitabine metabolism (unlike potential CYP2C9 interactions)
- Established safety profile in oncology populations 1
- Once-daily dosing improves adherence 3
While general hypertension guidelines recommend ACE inhibitors/ARBs for non-Black patients <55 years 4, 5, the cancer-specific guidance prioritizes CCBs for chemotherapy-induced hypertension due to their rapid onset and predictable response.
Critical Monitoring Parameters
- Reassess BP every 2 weeks during dose titration
- Hold capecitabine if BP ≥160/100 mmHg despite treatment
- Permanently discontinue capecitabine if hypertensive crisis occurs (BP ≥180/110 mmHg with end-organ damage)
- Monitor for resolution after completing chemotherapy—hypertension typically resolves within 3-236 days after last capecitabine dose 1
Special Considerations
For patients already on antihypertensives: Optimize existing regimen per standard guidelines 4, 5 rather than following the cancer-specific algorithm. The stepped approach above applies specifically to antihypertensive-naive patients.
Drug interactions: Capecitabine inhibits CYP2C9, which could theoretically affect metabolism of some antihypertensives, though this is not clinically significant with amlodipine 6. Exercise caution if using warfarin concurrently, as capecitabine significantly increases warfarin exposure.
Post-chemotherapy management: Arrange primary care follow-up within 4 weeks of stopping capecitabine to reassess need for ongoing antihypertensive therapy and prevent hypotension from unnecessary continuation 1.
Common Pitfalls to Avoid
- Don't delay chemotherapy unnecessarily—BP <160/100 mmHg is acceptable to proceed
- Don't use beta-blockers as first-line in this population (not preferred initial therapy per guidelines) 2, 5
- Don't combine ACE inhibitor with ARB—increases adverse events without benefit 7, 5
- Don't forget to de-escalate antihypertensives after completing chemotherapy to avoid iatrogenic hypotension